Fujita M., Inoue M., Tanizawa O., Minagawa J., Yamada T., Tani T.
Department of Obstetrics and Gynecology, Osaka University Medical School, Department of Obstetrics and Gynecology, Minoh City Hospital, and Department of Obstetrics and Gynecology, Osaka Kaisei Hospital, Osaka, Japan.
Int J Gynecol Cancer. 1993 Sep;3(5):329-335. doi: 10.1046/j.1525-1438.1993.03050329.x.
Forty-one patients with endodermal sinus tumors of the ovary (EST) (23: pure EST, nine: EST with dysgerminoma; and nine: EST with immature teratoma) were treated with cytoreductive surgery, with or without subsequent adjuvant chemotherapy including VAC or PVB. Clinical staging of these patients showed 23 in stage I, six in stage II and 12 in stage III and IV. The outcome was good in the patients with stage I or II disease, with 5- and 10-year survival rates of around 80%. In contrast, all except two patients with stage III or IV disease died within 2 years. Aggressive surgery did not change the outcome of patients with stage I disease. In addition, postoperative chemotherapy was necessary, but the choice of vincristine, actinomycin-D and cyclophosphamide (VAC) or cis-platin, vinblastine and bleomycin (PVB) did not make any difference. Based on the results of the present study, VAC or PVB chemotherapy, after cytoreductive surgery, is essential for cure and conservative surgery followed by VAC or PVB regimen should be recommended for young patients.
41例卵巢内胚窦瘤(EST)患者(23例:单纯EST,9例:EST合并无性细胞瘤;9例:EST合并未成熟畸胎瘤)接受了减瘤手术,部分患者术后接受了包括VAC或PVB方案在内的辅助化疗。这些患者的临床分期显示,23例为Ⅰ期,6例为Ⅱ期,12例为Ⅲ期和Ⅳ期。Ⅰ期或Ⅱ期疾病患者的预后良好,5年和10年生存率约为80%。相比之下,Ⅲ期或Ⅳ期疾病患者除2例之外均在2年内死亡。积极的手术并未改变Ⅰ期疾病患者的预后。此外,术后化疗是必要的,但选择长春新碱、放线菌素-D和环磷酰胺(VAC)或顺铂、长春花碱和博来霉素(PVB)并无差异。基于本研究结果,减瘤手术后进行VAC或PVB化疗对于治愈至关重要,对于年轻患者应推荐行保守手术,随后采用VAC或PVB方案。